Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...

There are two diabetes medications that are also used for weight loss – Rybelsus and Ozempic. They both contain the same drug called Semaglutide, Rybelsus is an oral medication whereas Ozempic is an ...

Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to ...

Switching From Tirzepatide to semaglutide for weight loss? This article was reviewed by Lynn Marie Morski, MD, JD. Key takeaways: You can switch from tirzepatide to ...

Ever since being granted approval by the FDA, the prescription injectable medication known as Ozempic has been on the lips of anyone looking for help to manage their type 2 diabetes and folks looking ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib ...

Lexaria Bioscience ( ($LEXX) ) just unveiled an update. Lexaria reported that its Phase 1b, 12‑week chronic study GLP-1-H24-4 in Australia met its ...

The US Food and Drug Administration today approved a pill version of the blockbuster anti-obesity drug Wegovy. Made by Novo ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically involves dieting or gym memberships, but for increasing numbers of overweight ...